Protalix signs supply deal with Brazilian govt

June 19, 2013 by The Associated Press

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease treatment.

The Israeli company said an arm of the Brazilian Ministry of Health has committed to buying at least $40 million of the drug annually during the seven-year agreement for Uplyso, which is marketed as Elelyso in the United States and Israel.

During the agreement, Protalix will transfer the technology needed for the Brazilian government to build at its own expense a factory to make a sustainable supply of Uplyso. Protalix doesn't have to complete the final stage of its technology transfer until the government has made at least $280 million in Uplyso purchases.

Protalix worked with ., the world's second-largest drugmaker, to develop Elelyso, and it will have to pay Pfizer a maximum of about $12.5 million from its annual profits generated in Brazil during the agreement. Pfizer returned its commercialization rights to the drug in Brazil to Protalix.

is a caused by deficiency of an important enzyme. The condition can cause liver and neurological problems.

The and Israeli regulators approved Elelyso last year, and Brazilian regulators approved it in March.

U.S.-traded shares of Protalix jumped 9.3 percent, or 47 cents, to $5.54 in premarket trading about two hours ahead of the market opening.

Explore further: EU approves Novartis-Incyte blood cancer drug

Related Stories

Pfizer will buy NextWave Pharma for up to $700M

October 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Elan enters $1B royalty deal with Theravance

May 13, 2013

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Recommended for you

Treatment options for opioid addiction are expanding

August 10, 2016

In the past two decades, the devastation associated with opioid addiction has escaped the relative confines of the inner city and extended to suburban and rural America. Due in large part to the proliferation of prescription ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.